1

We are pleased to announce the latest public release (DF6) of FinnGen results and summary statistics!

Follow these instructions to access the results

FinnGen brings together the nation-wide network of Finnish biobanks.

Every Finn can be a part of the FinnGen study by giving a biobank consent.
Samples available
522 500
Samples needed by 2023: 520 000
Current data freeze
392 000
combined genotype and health registry data

Samples from biobanks

The FinnGen study will utilise samples collected by a nationwide network of Finnish biobanks. The study is based on combining genome information with digital health care data from national health registries.
Read more: biobanks

Take part

Samples are needed from all over Finland in the thousands, because solutions in the field of personalized healthcare can be found only by looking at large masses. Every Finn can be a part of the FinnGen study by giving a biobank consent.
Read more: participation

Everybody benefits

The genome data produced during the project will be owned by the Finnish biobanks, and remain available for researcher purposes. The medical breakthroughs that arise from the project will eventually benefit health care systems and patients globally.
Read more: benefits

Collaboration is the key

The collaborative nature of the FinnGen research project is exceptional compared to many other studies. The study involves all the same actors as drug development. With this open cooperation, we hope to speed up the emergence of new innovations.
Read more: partners

Data freeze 6 results and summary statistics available!

Results can be browsed online using the FinnGen web browser and the summary statistics downloaded
This data freeze consists of >260,000 individuals, almost 17 M variants and >2,800 disease endpoints. To get more information about how to access the results and summary statistics, please follow this link:
Access results
Winter landscape with the FinnGen logo and the text: "FinnGen Data Freeze 6 results now available".

News

FinnGen Welcomes New Industry Partner Boehringer Ingelheim

Boehringer Ingelheim has joined FinnGen, a large-scale academic – industry, genome research collaboration in Finland aiming to collect and analyse genome and health data from 500,000 Finnish biobank participants.
Read more
Text "welcome" on a very colorful background.
5.10.2021

FinnGen research results integrated into Open Targets Genetics

Open Targets is an innovative, large-scale public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation. We are pleased to announce that the publicly available FinnGen results have now been integrated into the brand new version 5 of the Open Targets Genetics Portal!
Read more
A photo of Ian Dunham, the Director of Open Targets, and the following quote: "The rich phenotypic information and special characteristics of the FinnGen data make it a very high priority resource for Open Targets".
30.6.2021